Protectan CBLB502 was administered as a single injection at 48 hours post-exposure to 6.5 Gy doses of ionizing radiation, which results in approximately 75% mortality, if untreated (similar to doses received by Chernobyl firefighters). In the non-human primate model tested, approximately 67% of the Protectan CBLB502-treated animals survived compared to 25% of the control group.
Administration of CBLB502 48 hours post exposure was shown to increase survival, and have a significantly beneficial effect on platelet levels while also reducing the severity of radiation-induced neutropenia.